Jiao M - Search Results

1

First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions.

Jiang P, Geng L, Mao Z, Wang Q, Wang W, Jiao M, Yao Y, Chen N, Zhang J, Nan K, Shen Y, Guo H, Jiang L. Jiang P, et al. Among authors: jiao m. Immunotherapy. 2022 Mar 9. doi: 10.2217/imt-2021-0112. Online ahead of print. Immunotherapy. 2022. PMID: 35259921 Review.

2

Delisheng, a Chinese medicinal compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways.

Lu CX, Nan KJ, Nie YL, Hai YN, Jiao M. Lu CX, et al. Among authors: jiao m. Mol Biol Rep. 2010 Oct;37(7):3407-12. doi: 10.1007/s11033-009-9930-7. Epub 2009 Dec 11. Mol Biol Rep. 2010. PMID: 20012371 Free PMC article.

3

Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.

Jiao M, Nan KJ. Jiao M, et al. Int J Oncol. 2012 Feb;40(2):461-8. doi: 10.3892/ijo.2011.1197. Epub 2011 Sep 12. Int J Oncol. 2012. PMID: 21922131

4

Prognostic value of Notch-1 expression in hepatocellular carcinoma: a meta-analysis.

Wu T, Jiao M, Jing L, Wang MC, Sun HF, Li Q, Bai YY, Wei YC, Nan KJ, Guo H. Wu T, et al. Among authors: jiao m. Onco Targets Ther. 2015 Oct 22;8:3105-14. doi: 10.2147/OTT.S92945. eCollection 2015. Onco Targets Ther. 2015. PMID: 26543379 Free PMC article.

5

BMI-1, a promising therapeutic target for human cancer.

Wang MC, Li CL, Cui J, Jiao M, Wu T, Jing LI, Nan KJ. Wang MC, et al. Among authors: jiao m. Oncol Lett. 2015 Aug;10(2):583-588. doi: 10.3892/ol.2015.3361. Epub 2015 Jun 11. Oncol Lett. 2015. PMID: 26622537 Free PMC article.

6

Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study.

Wang MC, Jiao M, Wu T, Jing L, Cui J, Guo H, Tian T, Ruan ZP, Wei YC, Jiang LL, Sun HF, Huang LX, Nan KJ, Li CL. Wang MC, et al. Among authors: jiao m. Oncotarget. 2016 Feb 23;7(8):9586-99. doi: 10.18632/oncotarget.7078. Oncotarget. 2016. PMID: 26840020 Free PMC article.

7

Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma.

Jing L, Ruan Z, Sun H, Li Q, Han L, Huang L, Yu S, Wang Y, Guo H, Jiao M. Jing L, et al. Among authors: jiao m. J Cell Physiol. 2019 Aug;234(10):18448-18458. doi: 10.1002/jcp.28480. Epub 2019 Mar 25. J Cell Physiol. 2019. PMID: 30908631

8

Clinicopathological and prognostic significance of pretreatment thrombocytosis in patients with endometrial cancer: a meta-analysis.

Bai YY, Du L, Jing L, Tian T, Liang X, Jiao M, Nan KJ, Guo H, Ruan ZP. Bai YY, et al. Among authors: jiao m. Cancer Manag Res. 2019 May 8;11:4283-4295. doi: 10.2147/CMAR.S186535. eCollection 2019. Cancer Manag Res. 2019. PMID: 31190994 Free PMC article.

9

Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival.

Yu S, Wang Y, Hou J, Li W, Wang X, Xiang L, Tan D, Wang W, Jiang L, Claret FX, Jiao M, Guo H. Yu S, et al. Among authors: jiao m. PLoS One. 2020 Apr 2;15(4):e0231003. doi: 10.1371/journal.pone.0231003. eCollection 2020. PLoS One. 2020. PMID: 32240238 Free PMC article.

10

DARS-AS1 promotes clear cell renal cell carcinoma by sequestering miR-194-5p to up-regulate DARS.

Jiao M, Guo H, Chen Y, Li L, Zhang L. Jiao M, et al. Biomed Pharmacother. 2020 Aug;128:110323. doi: 10.1016/j.biopha.2020.110323. Epub 2020 Jun 8. Biomed Pharmacother. 2020. PMID: 32526457 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

735 results

Search Page

Filters